Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
Multidrug resistance (MDR) is the major cause of chemotherapy failure, which is usually caused by the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2. To date, no MDR modulator has been clinically approved. Here, we found that lazertinib (YH25448; a novel third-gene...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2022-03-01
|
| Серія: | Molecular Therapy: Oncolytics |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2372770522000237 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|